Merck: FDA approves Keytruda for gastric cancer
(CercleFinance.com) - Merck has announced that the US Food and Drug Administration (FDA) has approved Keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of certain gastric and gastroesophageal cancers.
This approval is based on data from a Phase III study showing a statistically significant 74% objective response in patients who received the Keytruda regimen, compared to 52% without.
Copyright (c) 2021 CercleFinance.com. All rights reserved.